Corium International,Inc. (NASDAQ:CORI) Files An 8-K Regulation FD Disclosure
Item7.01.Regulation FD.
Corium International,Inc. (the Company) is furnishing the
presentation materials attached as Exhibit99.1 to this report,
which the Company may use from time to time in meetings with
investors and other third parties. These presentation materials
also will be posted under the Investors section on the Companys
website at www.coriumintl.com. The Company does not undertake to
update these presentation materials.
The information furnished with this report, including
Exhibit99.1, shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference into any other
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
Item9.01.Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Presentation materials. |
About Corium International, Inc. (NASDAQ:CORI)
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch. Corium International, Inc. (NASDAQ:CORI) Recent Trading Information
Corium International, Inc. (NASDAQ:CORI) closed its last trading session down -0.16 at 3.72 with 39,862 shares trading hands.